Evaluation of Times-to-onset and Outcomes of Lung Adverse Events Associated With Sorafenib Using JADER
This study focused on lung AEs associated with sorafenib, highlighting serious outcomes such as lung metastases and tracheal hemorrhage. Continuous monitoring for these AEs is crucial from treatment initiation through the entire therapy course.
Authors
- R. Tomii
- Miku Anzai
- Yuko Kanbayashi (ORCID: https://orcid.org/0000-0002-0095-2293)
- NARU YAMAMOTO
- Tadashi Shimizu (ORCID: https://orcid.org/0000-0002-5563-6730)
- HARUKA WAKABAYASHI
- Mayako Uchida (ORCID: https://orcid.org/0000-0003-0507-7309)
Institutions
- Doshisha Women's College of Liberal Arts (JP)
- Hyogo University (JP)
- Osaka University of Pharmaceutical Sciences (JP)
Publication Details
- Journal
- In Vivo
- Published
- 2024-12-31
- DOI
- https://doi.org/10.21873/invivo.13836
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- Taiho Pharmaceutical